Showing of 9 results
Fabio Cominelli, MD discusses how his team of researchers discovered the specific blockade of interleukin-18 can reduce disease severity in colitis and new personalized therapies to put IBD in permanent remission.
Study will allow researchers to develop personalized precision medicine for treatment of IBD in this underrepresented minority patient population - Innovations in Digestive Health |Fall 2020
Innovations in Digestive Health | Fall 2021
UH Rainbow Babies & Children's Using Personalized Medicine Tool to Better Manage Kids and Teens with IBD
Program helps personalize dosing for infliximab - Innovations in Pediatrics | Fall 2021
Gut instincts - Innovations in Digestive Health | Winter 2020
UH Digestive Health Institute explores new IBD treatment using IL-1 targeted therapy UH Innovations in Digestive Health - Fall 2018 Fabio Cominelli, MD For 25 years, researchers have studied interleukin-1 (IL-1), a highly active proinflammatory...
New gastroenterologist is one of just two IBD specialists in the UH system UH Clinical Update - June 2018 Among gastrointestinal conditions, inflammatory bowel disease (IBD) is arguably among the most complex to manage. The disease, whether in the...
Research indicates strong role in development of cardiovascular disease University Hospitals Harrington Heart & Vascular Institute researchers Muhammad Panhwar, MD, and Mahazarin Ginwalla, MD, recently concluded a study of more than 22 million...